Boehringer Ingelheim is discarding an inhaled gene therapy designed to treat cystic fibrosis (CF) after terminating a phase 1 ...

Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash.

Krystal Biotech is strategically positioned in the biotech sector with its unique focus on developing genetic medicines for rare diseases, offering a promising investment opportunity. Krystal ...

These two biotechs only have one marketable therapy each, but both have blockbuster potential.

Plant biotechnology has revolutionised our ability to enhance crop performance, conserve endangered species and understand the intricate genetic architectures underlying plant diversity. This field ...

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, was honored to accept the ...

Genetic engineering, also known as genetic modification, is a set of technologies used to change the genetic makeup of cells, including the transfer of genes within and across species boundaries to ...

Transcription and translation are processes a cell uses to make all proteins the body needs to function from information stored in the sequence of bases in DNA. The four bases (C, A, T/U, and G in the ...

AMSTERDAM--(BUSINESS WIRE)--Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced that it has entered into a Cooperative ...

“The new WIPO Treaty on Patents, Genetic Resources, and Traditional Knowledge has the potential to transform global biotechnology, promoting a fairer distribution of benefits and strengthening the ...

Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of which has no FDA-approved treatments. Now the ...